Follow The Filings

DYN Dyne Therapeutics

Dyne Therapeutics earnings company data as of 4:45 AM ET 11/1

Scheduled

1 period, newest first, nothing reported yet. Each row shows EPS above revenue.

Period Date Metric Estimate Actual Result
FY2026 Q3 4 Nov EPS -0.89 — —
Rev — — —

Insider trades

Open-market buys and sales by DYN's executives, directors and 10% owners in the last 12 months, from their Form 4s

All DYN insider trades
  • $315K bought by 1 insider
  • None no sales outside a trading plan
  • $168M sold by 2 insiders under 10b5-1 plans
  1. Brian S Posner Director
    Buy
    $40K 2,500 shares at $16.00 +10% to stake
    Traded Oct 2 Filed Oct 6
    ↗
  2. Jason P Rhodes Director
    Planned sale
    $65.2M 2,586,928 shares at $25.20 86% of stake
    Traded Aug 13–14 Filed Aug 17
    ↗
  3. Dirk Kersten Director
    Planned sale
    $6.7M 261,460 shares at $25.51 6.8% of stake
    Traded Jul 27 Filed Jul 29
    ↗
  4. Jason P Rhodes Director
    Planned sale
    $17.9M 777,451 shares at $22.97 100% of stake
    Traded Jul 6–7 Filed Jul 8
    ↗
  5. Jason P Rhodes Director
    Planned sale
    $10.7M 504,695 shares at $21.23 34% of stake
    Traded Jun 26–29 Filed Jun 30
    ↗
  6. Jason P Rhodes Director
    Planned sale
    $5.6M 267,760 shares at $21.09 20% of stake
    Traded Jun 23–25 Filed Jun 26
    ↗
  7. Dirk Kersten Director
    Planned sale
    $5.5M 263,962 shares at $20.70 6.4% of stake
    Traded Jun 22–23 Filed Jun 24
    ↗
  8. Dirk Kersten Director
    Planned sale
    $1.7M 84,355 shares at $20.10 2% of stake
    Traded Jun 17–18 Filed Jun 22
    ↗
  9. Brian S Posner Director
    Buy
    $34K 2,000 shares at $16.94 +8.9% to stake
    Traded Jun 8 Filed Jun 9
    ↗
  10. Brian S Posner Director
    Buy
    $44K 2,500 shares at $17.48 +13% to stake
    Traded Jun 3 Filed Jun 5
    ↗
  11. Brian S Posner Director
    Buy
    $36K 2,000 shares at $18.21 +11% to stake
    Traded May 26 Filed May 28
    ↗
  12. Brian S Posner Director
    Buy
    $43K 2,500 shares at $17.12 +16% to stake
    Traded May 20 Filed May 22
    ↗
  13. Jason P Rhodes Director
    Planned sale
    $1.9M 106,723 shares at $18.14 8.6% of stake
    Traded May 4–6 Filed May 6
    ↗
  14. Jason P Rhodes Director
    Planned sale
    $4.2M 227,337 shares at $18.38 16% of stake
    Traded Apr 28 Filed Apr 30
    ↗
  15. Jason P Rhodes Director
    Planned sale
    $7.1M 384,549 shares at $18.47 24% of stake
    Traded Apr 23–27 Filed Apr 27
    ↗

Also filed in the last 12 months, not counted as buying or selling: 24 sales to cover taxes, 5 stock grants, and 1 gift.

SEC filings

Recent issuer filings from EDGAR, 13 shown.

Filed Form Detail Links
8-K 7.01,8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
424B5 Filing Doc
424B5 Filing Doc
8-K 8.01 Filing Doc
8-K 5.02 Filing Doc
8-K 1.01,2.03 Filing Doc

Source: SEC EDGAR submissions, updated 10 days ago. All on EDGAR

Estimates are consensus figures; SEC filings remain the official record. Not investment advice.